Full FDA hold de­rails clin­i­cal study of Ful­crum drug in a no good, very bad week for sick­le cell R&D

The roller-coast­er ride of highs and lows at Cam­bridge, MA-based Ful­crum Ther­a­peu­tics just took a sick­en­ing plunge.

Weeks af­ter us­ing some up­beat re­sults to set the stage for a $125 mil­lion raise — no easy feat in this mar­ket — the Ful­crum team got hit with a full clin­i­cal hold on one of their top drugs. And the news ripped up a chunk of mar­ket val­ue that sent shares $FULC tum­bling more than 50% Fri­day morn­ing.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN